Design Therapeutics (NASDAQ:DSGN) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Design Therapeutics (NASDAQ:DSGN) released its earnings results on Wednesday. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06, FiscalAI reports.

Design Therapeutics Trading Up 2.8%

DSGN traded up $0.29 during trading on Wednesday, hitting $10.63. 314,980 shares of the company traded hands, compared to its average volume of 441,931. The company has a market cap of $665.23 million, a PE ratio of -9.01 and a beta of 1.73. The stock’s 50-day simple moving average is $12.36 and its two-hundred day simple moving average is $12.14. Design Therapeutics has a 1 year low of $6.23 and a 1 year high of $17.25.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Design Therapeutics in a report on Thursday, October 15th. Wells Fargo & Company began coverage on shares of Design Therapeutics in a research note on Friday, October 2nd. They issued an “overweight” rating and a $26.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.86.

Design Therapeutics Company Profile

Design Therapeutics, Inc (NASDAQ: DSGN) is a clinical-stage biotechnology company developing small-molecule medicines for genetic diseases caused by nucleotide repeat expansions. The company’s GeneTAC, or gene-targeted activation compound, platform is designed to reactivate genes that have been silenced by these repeat expansions, with the goal of restoring production of beneficial proteins.

The company’s research has focused on disorders affecting the nervous system, muscles and eyes.